Skip to main content

FDA Approvals

Payers' Guide, FDA Approvals

Iclusig: A New Treatment Option for Adults with CML or Ph+ ALL that Is Resistant/ Intolerant to Previous Therapy with TKIs

Lynne Lederman, PhD, Medical Writer

Payers' Guide, FDA Approvals

Qsymia: Combination Oral Therapy a New Weight-Loss Option for Obese or Overweight Patients

Payers' Guide, FDA Approvals

Rayos: A Novel Oral Delayed-Release Prednisone for the Treatment of Rheumatoid Arthritis and Other Inflammatory Diseases

Alice Goodman, Medical Writer

Payers' Guide, FDA Approvals

Xeljanz: A New Treatment Option for Patients with Rheumatoid Arthritis

Alice Goodman, Medical Writer

Payers' Guide, FDA Approvals

Tudorza Pressair: A Novel Oral Inhalation Therapy for the Maintenance Treatment of Chronic Obstructive Pulmonary Disease–Associated Bronchospasm

Payers' Guide, FDA Approvals

Vascepa: First EPA-Only Omega-3 Therapy Approved by the FDA for Severe Hypertriglyceridemia

Payers' Guide, FDA Approvals

Eliquis Approved by the FDA to Reduce the Risks of Stroke and Systemic Embolism in Patients with Atrial Fibrillation

Payers' Guide, FDA Approvals

The Health Burden of Multiple Myeloma: Subcutaneous Velcade a New, Convenient Route of Administration Option

Rhonda Williams, Medical Writer

Payers' Guide, FDA Approvals

Kyprolis: A New Treatment Option for Patients with Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib and an Immunomodulatory Agent

Lynne Lederman, PhD, Medical Writer

Payers' Guide, FDA Approvals

Jentadueto: A New Oral Antihyperglycemic Combination Therapy for Patients with Type 2 Diabetes

Wayne Kuznar, Medical Writer

Page 48 of 53
Results 471 - 480 of 522